Pharmacodynamics
Assessments of pharmacodynamics (PD) in the initial stages of drug development are vital for gathering data on how drugs affect biological systems. With this critical information, bioanalytical strategies can be further refined for subsequent clinical studies, ultimately improving treatment outcomes. PD biomarkers are extensively employed in both preclinical and clinical investigations to establish optimal dosing schedules and assess therapeutic effectiveness.
Expertise With Pharmacodynamic
(PD) Assessments:
Extensive Experience
Expertise across a diverse range of assays, including those for measuring soluble biomarkers, molecular events, and cellular phenotyping, ensuring reliable and reproducible results.
Quality Compliance
We understand regulatory expectations for biomarker analytical validations based on the context of use.
Leaders in PD Assays
We offer Australia’s most comprehensive array of pharmacodynamics (PD) assays.
360biolabs Bioanalytical Services
Biomarkers
Assess biological indicators of normal biological processes, disease progression, or responses to treatment interventions via our diverse platforms.
Molecular Assays
Qualitatively or quantitatively measure the presence, amount, or functional activity of a target entity using qPCR or digital PCR.
Flow Cytometry
Our advanced platforms and extensive expertise can assess a varied range of cellular responses using flow cytometry.
Related Content
Blog: Flow Cytometry
Read our latest blog on Flow Cytometry in Clinical Trials: A Powerful and Versatile Tool.
Blog: Biomarkers
Read about our experience with biomarkers in our latest blog: Biomarkers as Tools to Assess and Predict Clinical Efficacy.
Australian Locations
Our purpose-built facilities in Melbourne and Brisbane are situated in medical research precincts and allow assaying time-sensitive samples.